• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Cardiovascular disease and cancer are the 2 leading causes of death worldwide. Emerging
evidence suggests common mechanisms between cancer and cardiovascular disease …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Cancer patients are at an increased risk of developing atrial fibrillation (AF) and thrombosis.
However, the management of anticoagulation in patients with both diseases may be …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Background It is unclear whether newly diagnosed cancer adds to the risk of arterial
thromboembolism (ATE) in patients with atrial fibrillation/flutter (AF). This is especially …

Background The incidence of atrial fibrillation (AF) associated with anticancer drugs in
cancer patients remains incompletely defined. Objectives The primary outcome was the …

Aims Multiple risk scores to predict ischaemic stroke (IS) in patients with atrial fibrillation (AF)
have been developed. This study aims to systematically review these scores, their …

Background Patients with myeloproliferative neoplasms (MPNs), essential thrombocythemia
(ET), polycythemia vera (PV), and myelofibrosis (MF), have increased risk of cardiovascular …

Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer
therapies is a key component of cardio-oncology, aiming to reduce cardiovascular …